Francis H Glorieux

List of Publications by Year
in descending order

206 papers	23,746 citations	12597 71 h-index	8878 150 g-index
213 all docs	213 docs citations	213 times ranked	13822 citing authors

#	Article	IF	Citations
1	Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet Journal of Rare Diseases, 2022, 17, 30.	1.2	6
2	Predicting ambulatory function at skeletal maturity in children with moderate to severe osteogenesis imperfecta. European Journal of Pediatrics, 2021, 180, 233-239.	1.3	8
3	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 2021, 108, 622-633.	1.5	26
4	Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I. International Journal of Molecular Sciences, 2021, 22, 4508.	1.8	15
5	Lung Transplantation in a Patient With Osteogenesis Imperfecta and Osteoporosis. Journal of the Endocrine Society, 2021, 5, A205-A205.	0.1	0
6	Multisite longitudinal calibration of HR-pQCT scanners and precision in osteogenesis imperfecta. Bone, 2021, 147, 115880.	1.4	6
7	Osteogenesis imperfecta tooth level phenotype analysis: Cross-sectional study. Bone, 2021, 147, 115917.	1.4	7
8	HRâ€pQCT Measures of Bone Microarchitecture Predict Fracture: Systematic Review and Metaâ€Analysis. Journal of Bone and Mineral Research, 2020, 35, 446-459.	3.1	92
9	Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study. American Journal of Medical Genetics, Part A, 2020, 182, 697-704.	0.7	17
10	Perspectives on the evolution of genetic counselling: Experience over three decades in a family with recurrent lethal osteogenesis imperfecta. Molecular Genetics and Metabolism, 2020, 131, 114-115.	0.5	0
11	Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles. Bone, 2020, 140, 115547.	1.4	8
12	Musculoskeletal phenotype in two unrelated individuals with a recurrent nonsense variant in SGMS2. Bone, 2020, 134, 115261.	1.4	14
13	Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genetics in Medicine, 2019, 21, 275-283.	1.1	34
14	Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height. Journal of Bone and Mineral Research, 2019, 34, 2198-2204.	3.1	9
15	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. JBMR Plus, 2019, 3, e10118.	1.3	22
16	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet, The, 2019, 393, 2416-2427.	6.3	229
17	Mobility in osteogenesis imperfecta: a multicenter North American study. Genetics in Medicine, 2019, 21, 2311-2318.	1.1	15
18	Caries prevalence and experience in individuals with osteogenesis imperfecta: A crossâ€sectional multicenter study. Special Care in Dentistry, 2019, 39, 214-219.	0.4	11

#	Article	IF	Citations
19	Coneâ€Beam Computed Tomography of Osteogenesis Imperfecta Types III and IV: Threeâ€Dimensional Evaluation of Craniofacial Features and Upper Airways. JBMR Plus, 2019, 3, e10124.	1.3	11
20	Oro-dental and cranio-facial characteristics of osteogenesis imperfecta type V. European Journal of Medical Genetics, 2019, 62, 103606.	0.7	11
21	OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH). Journal of the Endocrine Society, 2019, 3, .	0.1	0
22	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clinical Genetics, 2018, 94, 502-511.	1.0	33
23	Muscle Function in Osteogenesis Imperfecta Type IV. Calcified Tissue International, 2017, 101, 362-370.	1.5	19
24	Learning from the experience of a long-standing interprofessional osteogenesis imperfecta clinic: A case study evaluation. Journal of Interprofessional Education and Practice, 2017, 7, 54-60.	0.2	0
25	Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation. Journal of Bone and Mineral Research, 2017, 32, 1884-1892.	3.1	55
26	BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. Journal of Bone and Mineral Research, 2017, 32, 1496-1504.	3.1	107
27	Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2017, 32, 1034-1039.	3.1	35
28	Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone, 2017, 95, 151-161.	1.4	66
29	Spondyloepimetaphysial Dysplasia with Joint Laxity in Three Siblings with B3GALT6 Mutations. Molecular Syndromology, 2017, 8, 303-307.	0.3	7
30	Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years. Journal of Bone and Mineral Research, 2016, 31, 347-357.	3.1	57
31	Evidence for a Role for Nanoporosity and Pyridinoline Content in Human Mild Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2016, 31, 1050-1059.	3.1	36
32	Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Reports, 2016, 5, 158-162.	0.2	47
33	Pharmacokinetics and pharmacodynamics of a human monoclonal antiâ€FGF23 antibody (KRN23) in the first multiple ascendingâ€dose trial treating adults with Xâ€linked hypophosphatemia. Journal of Clinical Pharmacology, 2016, 56, 176-185.	1.0	38
34	Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3516-3525.	1.8	28
35	Body Composition in Children and Adolescents with OsteogenesisÂImperfecta. Journal of Pediatrics, 2016, 169, 232-237.	0.9	28
36	Osteogenesis Imperfecta Type VI in Individuals from Northern Canada. Calcified Tissue International, 2016, 98, 566-572.	1.5	30

#	Article	IF	Citations
37	Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial. Bone, 2016, 86, 36-42.	1.4	29
38	Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations â€" genotypeâ€"phenotype correlations and effect of bisphosphonate treatment. Bone, 2016, 86, 53-57.	1.4	58
39	Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta. Calcified Tissue International, 2016, 98, 42-48.	1.5	7
40	Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions. Calcified Tissue International, 2016, 98, 76-84.	1.5	32
41	Involving Families with Osteogenesis Imperfecta in Health Service Research: Joint Development of the OI/ECE Questionnaire. PLoS ONE, 2016, 11, e0147654.	1.1	8
42	Osteotomy Healing in Children With Osteogenesis Imperfecta Receiving Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2015, 30, 1362-1368.	3.1	56
43	Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Journal of Bone and Mineral Research, 2015, 30, 2150-2157.	3.1	107
44	Homozygosity for Frameshift Mutations in XYLT2 Result in a Spondylo-Ocular Syndrome with Bone Fragility, Cataracts, and Hearing Defects. American Journal of Human Genetics, 2015, 96, 971-978.	2.6	65
45	The functional muscleâ€"bone unit in patients with osteogenesis imperfecta type I. Bone, 2015, 79, 52-57.	1.4	46
46	Cole-Carpenter Syndrome Is Caused by a Heterozygous Missense Mutation in P4HB. American Journal of Human Genetics, 2015, 96, 425-431.	2.6	92
47	Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone. Bone, 2015, 73, 233-241.	1.4	48
48	Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1834-1839.	0.5	45
49	Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2565-2573.	1.8	141
50	The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI. Bone, 2015, 76, 115-120.	1.4	21
51	A polyadenylation site variant causes transcript-specific BMP1 deficiency and frequent fractures in children. Human Molecular Genetics, 2015, 24, 516-524.	1.4	37
52	Normal Bone Density and Fat Mass in HeterozygousSERPINF1Mutation Carriers. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2446-E2450.	1.8	10
53	Osteoporosis Caused by Mutations in PLS3: Clinical and Bone Tissue Characteristics. Journal of Bone and Mineral Research, 2014, 29, 1805-1814.	3.1	78
54	A Novel IFITM5 Mutation in Severe Atypical Osteogenesis Imperfecta Type VI Impairs Osteoblast Production of Pigment Epithelium-Derived Factor. Journal of Bone and Mineral Research, 2014, 29, 1402-1411.	3.1	63

#	Article	IF	Citations
55	Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations. Bone, 2014, 60, 122-128.	1.4	61
56	Muscle Anatomy and Dynamic Muscle Function in Osteogenesis Imperfecta Type I. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E356-E362.	1.8	54
57	Vitamin D/dietary calcium deficiency rickets and pseudo-vitamin D deficiency rickets. BoneKEy Reports, 2014, 3, 524.	2.7	35
58	Circulating Sclerostin in Children and Young Adults with Heritable Bone Disorders. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E920-E925.	1.8	22
59	Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone, 2014, 67, 56-62.	1.4	59
60	Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations. Bone, 2014, 67, 63-70.	1.4	44
61	Targeted Sequencing of a Pediatric Metabolic Bone Gene Panel Using a Desktop Semiconductor Next-Generation Sequencer. Calcified Tissue International, 2014, 95, 323-331.	1.5	22
62	Shaping and managing the course of a child's disease: Parental experiences with osteogenesis imperfecta. Disability and Health Journal, 2014, 7, 343-349.	1.6	27
63	Evaluation of the severity of malocclusions in children affected by osteogenesis imperfecta with the peer assessment rating and discrepancy indexes. American Journal of Orthodontics and Dentofacial Orthopedics, 2013, 143, 336-341.	0.8	41
64	Metaphyseal Dysplasia with Maxillary Hypoplasia and Brachydactyly Is Caused by a Duplication in RUNX2. American Journal of Human Genetics, 2013, 92, 252-258.	2.6	29
65	Mutations in WNT1 are a cause of osteogenesis imperfecta. Journal of Medical Genetics, 2013, 50, 345-348.	1.5	162
66	The impact of severe osteogenesis imperfecta on the lives of young patients and their parents â€“ a qualitative analysis. BMC Pediatrics, 2013, 13, 153.	0.7	57
67	Cortical and Trabecular Bone Density in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E954-E961.	1.8	62
68	The Muscle-Bone Relationship in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E990-E995.	1.8	41
69	Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of theIFITM5c.â^'14C>T mutation in all patients. Journal of Medical Genetics, 2013, 50, 21-24.	1.5	101
70	Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. Journal of Bone and Mineral Research, 2013, 28, 2001-2007.	3.1	75
71	Osteogenesis Imperfecta, an Ever-Expanding Conundrum. Journal of Bone and Mineral Research, 2013, 28, 1519-1522.	3.1	15
72	Emerging concepts in pediatric bone disease. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 346.	1.2	0

#	Article	IF	Citations
73	Lack of Circulating Pigment Epithelium-Derived Factor Is a Marker of Osteogenesis Imperfecta Type VI. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1550-E1556.	1.8	59
74	Serum 24,25-Dihydroxyvitamin D Concentrations in Osteogenesis Imperfecta: Relationship to Bone Parameters. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1243-1249.	1.8	15
75	Low bone mass and high material bone density in two patients with Loeys-Dietz syndrome caused by transforming growth factor beta receptor 2 mutations. Journal of Bone and Mineral Research, 2012, 27, 713-718.	3.1	25
76	Activities and participation in young adults with Osteogenesis Imperfecta. Journal of Pediatric Rehabilitation Medicine, 2011, 4, 13-22.	0.3	32
77	Cranial base abnormalities in osteogenesis imperfecta: Phenotypic and genotypic determinants. Journal of Bone and Mineral Research, 2011, 26, 405-413.	3.1	51
78	Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: Histomorphometric study. Journal of Bone and Mineral Research, 2011, 26, 2245-2251.	3.1	28
79	Mutations in SERPINF1 cause osteogenesis imperfecta type VI. Journal of Bone and Mineral Research, 2011, 26, 2798-2803.	3.1	164
80	Predictors and Correlates of Vitamin D Status in Children and Adolescents with Osteogenesis Imperfecta. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3193-3198.	1.8	32
81	Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. Journal of Bone and Mineral Research, 2010, 25, 1367-1374.	3.1	109
82	Deficient Bone Formation in Idiopathic Juvenile Osteoporosis: A Histomorphometric Study of Cancellous Iliac Bone. Journal of Bone and Mineral Research, 2010, 15, 957-963.	3.1	77
83	Genotypeâ€“phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. European Journal of Human Genetics, 2010, 18, 642-647.	1.4	90
84	Bisphosphonate Associated Osteonecrosis of the Jaw. Journal of Rheumatology, 2009, 36, 478-490.	1.0	173
85	Intravenous Pamidronate in Osteogenesis Imperfecta Type VII. Calcified Tissue International, 2009, 84, 203-209.	1.5	14
86	Large Osteoclasts in Pediatric Osteogenesis Imperfecta Patients Receiving Intravenous Pamidronate. Journal of Bone and Mineral Research, 2009, 24, 669-674.	3.1	27
87	Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. Journal of Bone and Mineral Research, 2009, 24, 1282-1289.	3.1	98
88	LDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Obstetrical and Gynecological Survey, 2009, 64, 240-242.	0.2	2
89	Osteogenesis Imperfecta: Update on presentation and management. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 153-160.	2.6	139
90	Evidence that Abnormal High Bone Mineralization in Growing Children with Osteogenesis Imperfecta is not Associated with Specific Collagen Mutations. Calcified Tissue International, 2008, 82, 263-270.	1.5	115

#	Article	IF	Citations
91	Hyperplastic callus formation in osteogenesis imperfecta typeÂV: follow-up of three generations over ten years. Skeletal Radiology, 2008, 37, 465-467.	1.2	28
92	Osteogenesis imperfecta. Best Practice and Research in Clinical Rheumatology, 2008, 22, 85-100.	1.4	146
93	Tooth Extraction Socket Healing in Pediatric Patients Treated with Intravenous Pamidronate. Journal of Pediatrics, 2008, 153, 719-720.	0.9	67
94	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology, 2008, 35, 1391-7.	1.0	120
95	Experience With Bisphosphonates in Osteogenesis Imperfecta. Pediatrics, 2007, 119, S163-S165.	1.0	93
96	Treatment of Osteogenesis Imperfecta: Who, Why, What?. Hormone Research in Paediatrics, 2007, 68, 8-11.	0.8	21
97	Intracortical remodeling during human bone developmentâ€"A histomorphometric study. Bone, 2007, 40, 274-280.	1.4	77
98	Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment. Bone, 2007, 40, 638-644.	1.4	94
99	Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone, 2007, 40, 821-827.	1.4	104
100	Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Human Mutation, 2007, 28, 209-221.	1.1	620
101	Natural History of Hyperplastic Callus Formation in Osteogenesis Imperfecta Type V. Journal of Bone and Mineral Research, 2007, 22, 1181-1186.	3.1	71
102	Bisphosphonates in Osteogenesis Imperfecta. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 159-164.	1.3	2
103	Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone, 2006, 39, 616-622.	1.4	88
104	Medical Therapy of Children With Fibrous Dysplasia. Journal of Bone and Mineral Research, 2006, 21, P110-P113.	3.1	30
105	CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta. Cell, 2006, 127, 291-304.	13.5	465
106	The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V. Bone, 2006, 38, 13-20.	1.4	53
107	Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone, 2006, 39, 901-906.	1.4	130
108	Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. Journal of Pediatrics, 2006, 148, 456-460.	0.9	96

#	Article	IF	Citations
109	Cellular Activity on the Seven Surfaces of Iliac Bone: A Histomorphometric Study in Children and Adolescents. Journal of Bone and Mineral Research, 2006, 21, 513-519.	3.1	45
110	Treatment of children with osteogenesis imperfecta. Current Osteoporosis Reports, 2006, 4, 159-164.	1.5	39
111	Pamidronate in Children and Adolescents with Osteogenesis Imperfecta: Effect of Treatment Discontinuation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1268-1274.	1.8	97
112	Pamidronate in Children with Osteogenesis Imperfecta: Histomorphometric Effects of Long-Term Therapy. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 511-516.	1.8	100
113	Treatment of children with osteogenesis imperfecta. Current Osteoporosis Reports, 2006, 4, 159-164.	1.5	3
114	Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome. Journal of Bone and Mineral Research, 2005, 20, 1235-1243.	3.1	132
115	Cyclical Intravenous Pamidronate Treatment Affects Metaphyseal Modeling in Growing Patients With Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2005, 21, 374-379.	3.1	72
116	Osteogenesis imperfecta, current and future medical treatment. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2005, 139C, 31-37.	0.7	59
117	Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?. Annals of Medicine, 2005, 37, 295-302.	1.5	50
118	High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone, 2005, 37, 634-641.	1.4	37
119	Caffey disease: an unlikely collagenopathy. Journal of Clinical Investigation, 2005, 115, 1142-1144.	3.9	48
120	Bone mineralization and growth are enhanced in preterm infants fed an isocaloric, nutrient-enriched preterm formula through term. American Journal of Clinical Nutrition, 2004, 80, 1595-1603.	2.2	56
121	Sclerotic Metaphyseal Lines in a Child Treated With Pamidronate: Histomorphometric Analysis. Journal of Bone and Mineral Research, 2004, 19, 1191-1193.	3.1	77
122	Maternal and Fetal Outcome After Long-Term Pamidronate Treatment Before Conception: A Report of Two Cases. Journal of Bone and Mineral Research, 2004, 19, 1742-1745.	3.1	97
123	Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate. Journal of Bone and Mineral Research, 2004, 19, 1779-1786.	3.1	226
124	Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone, 2004, 35, 231-234.	1.4	68
125	Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder?. Bone, 2004, 35, 1023-1028.	1.4	10
126	Osteogenesis imperfecta. Lancet, The, 2004, 363, 1377-1385.	6.3	1,084

#	Article	IF	Citations
127	Functional Analysis of Upper Limb Deformities in Osteogenesis Imperfecta. Journal of Pediatric Orthopaedics, 2004, 24, 689-694.	0.6	34
128	Positive Linear Growth and Bone Responses to Growth Hormone Treatment in Children With Types III and IV Osteogenesis Imperfecta: High Predictive Value of the Carboxyterminal Propeptide of Type I Procollagen. Journal of Bone and Mineral Research, 2003, 18, 237-243.	3.1	93
129	Bone Mass, Size, and Density in Children and Adolescents With Osteogenesis Imperfecta: Effect of Intravenous Pamidronate Therapy. Journal of Bone and Mineral Research, 2003, 18, 610-614.	3.1	167
130	Rescue of the Pseudo-Vitamin D Deficiency Rickets Phenotype of CYP27B1-Deficient Mice by Treatment With 1,25-Dihydroxyvitamin D3: Biochemical, Histomorphometric, and Biomechanical Analyses. Journal of Bone and Mineral Research, 2003, 18, 637-643.	3.1	99
131	Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1Î±-hydroxylase (CYP27B1). Journal of Cellular Biochemistry, 2003, 88, 245-251.	1.2	40
132	Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4569-4575.	1.8	200
133	Safety Profile of Frequent Short Courses of Oral Glucocorticoids in Acute Pediatric Asthma: Impact on Bone Metabolism, Bone Density, and Adrenal Function. Pediatrics, 2003, 111, 376-383.	1.0	116
134	Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 986-992.	1.8	127
135	Modern approach to children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics Part B, 2003, 12, 77-87.	0.3	29
136	Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV. Pediatrics, 2003, 111, 1030-1036.	1.0	165
137	Rapid Increase in Grip Force After Start of Pamidronate Therapy in Children and Adolescents With Severe Osteogenesis Imperfecta. Pediatrics, 2003, 111, e601-e603.	1.0	63
138	Modern approach to children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics Part B, 2003, 12, 77-87.	0.3	102
139	Influence of Dietary Cholesterol on Vitamin D Metabolism in Formula-Fed Preterm Neonates. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, 180-184.	0.9	4
140	Title is missing!. Journal of Pediatric Orthopaedics, 2002, 22, 622-625.	0.6	9
141	Urinary Excretion of Cross-Linked N-Telopeptides of Type 1 Collagen to Assess Bone Resorption in Infants From Birth to 1 Year of Age. Pediatrics, 2002, 110, 105-109.	1.0	13
142	Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone, 2002, 31, 19-25.	1.4	66
143	Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect. Journal of Bone and Mineral Research, 2002, 17, 30-38.	3.1	403
144	Bone Mineralization in Polyostotic Fibrous Dysplasia: Histomorphometric Analysis. Journal of Bone and Mineral Research, 2002, 17, 1949-1953.	3.1	25

#	Article	IF	Citations
145	The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation, 2002, 110, 1293-1299.	3.9	231
146	The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation, 2002, 110, 1293-1299.	3.9	137
147	Acetabular protrusion in osteogenesis imperfecta. Journal of Pediatric Orthopaedics, 2002, 22, 622-5.	0.6	10
148	LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. Cell, 2001, 107, 513-523.	13.5	2,055
149	A disease of the osteoblast. Lancet, The, 2001, 358, S45.	6.3	16
150	Targeted Inactivation of the 25-Hydroxyvitamin D3-1Î±-Hydroxylase Gene (CYP27B1) Creates an Animal Model of Pseudovitamin D-Deficiency Rickets*. Endocrinology, 2001, 142, 3135-3141.	1.4	358
151	Ã‰tiologie molÃ©culaire des rachitismes vitamino-dÃ©pendants hÃ©rÃ©ditaires. Medecine/Sciences, 2001, 17, 1289-1296.	0.0	4
152	Perinatal metabolism of vitamin D. American Journal of Clinical Nutrition, 2000, 71, 1317S-1324S.	2.2	253
153	Medical treatment of osteogenesis imperfecta. Drug Development Research, 2000, 49, 141-145.	1.4	2
154	Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease. Journal of Bone and Mineral Research, 2000, 15, 1650-1658.	3.1	440
155	Deficient Mineralization of Intramembranous Bone in Vitamin D-24-Hydroxylase-Ablated Mice Is Due to Elevated 1,25-Dihydroxyvitamin D and Not to the Absence of 24,25-Dihydroxyvitamin D*. Endocrinology, 2000, 141, 2658-2666.	1.4	257
156	Pamidronate Treatment of Severe Osteogenesis Imperfecta in Children under 3 Years of Age*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1846-1850.	1.8	230
157	Normative data for iliac bone histomorphometry in growing children. Bone, 2000, 26, 103-109.	1.4	302
158	Interpretation of bone mineral density values in pediatric Crohn's disease. Inflammatory Bowel Diseases, 1998, 4, 261-267.	0.9	68
159	Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta. New England Journal of Medicine, 1998, 339, 947-952.	13.9	889
160	Editorial: 24, 25-Dihydroxyvitamin Dâ€"Active Metabolite or Inactive Catabolite?. Endocrinology, 1998, 139, 3371-3374.	1.4	32
161	Bone-Specific Expression of the Alpha Chain of the Nascent Polypeptide-Associated Complex, a Coactivator Potentiating c-Jun-Mediated Transcription. Molecular and Cellular Biology, 1998, 18, 1312-1321.	1.1	79
162	Interpretation of Bone Mineral Density Values in Pediatric CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 1998, 4, 261-267.	0.9	48

#	Article	IF	Citations
163	Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Human Molecular Genetics, 1997, 6, 539-549.	1.4	184
164	Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in GÎ±s from patients with fibrous dysplasia of bone. Bone, 1997, 21, 201-206.	1.4	107
165	The 25-Hydroxyvitamin D 1-Alpha-Hydroxylase Gene Maps to the Pseudovitamin D-Deficiency Rickets (PDDR) Disease Locus. Journal of Bone and Mineral Research, 1997, 12, 1552-1559.	3.1	290
166	Aberrant splicing of the type III procollagen mRNA leads to intracellular degradation of the protein in a patient with ehlers-danlos type IV. Human Mutation, 1995, 6, 116-125.	1.1	12
167	Increased Expression of the c-fosProto-Oncogene in Bone from Patients with Fibrous Dysplasia. New England Journal of Medicine, 1995, 332, 1546-1551.	13.9	166
168	Assessment of bone mineral content in infants: the new age. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 709-710.	0.7	31
169	Human 25-hydroxyvitamin D 24-hydroxylase cytochrome P450 subunit maps to a different chromosomal location than that of pseudovitamin D-deficient rickets. Journal of Bone and Mineral Research, 1993, 8, 1397-1406.	3.1	12
170	Panostotic Fibrous Dysplasia A New Craniotubular Dysplasia. Clinical Nuclear Medicine, 1992, 17, 556-560.	0.7	5
171	Dual Energy X-Ray Absorptiometry Measurement of Bone Mineral Content in Newborns: Validation of the Technique. Pediatric Research, 1992, 32, 77-80.	1.1	105
172	Lumbar bone mineral content measured by dual energy Xâ€ray absorptiometry in newborns and infants. Acta Paediatrica, International Journal of Paediatrics, 1992, 81, 953-958.	0.7	108
173	Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13â€“14. Journal of Bone and Mineral Research, 1992, 7, 1447-1453.	3.1	88
174	Rickets, the Continuing Challenge. New England Journal of Medicine, 1991, 325, 1875-1877.	13.9	33
175	In vivo osteogenic activity of isolated human bone cells. Journal of Bone and Mineral Research, 1991, 6, 45-51.	3.1	30
176	Role of the source of phosphate salt in improving the mineral balance of parenterally fed low birth weight infants. Journal of Pediatrics, 1990, 116, 765-772.	0.9	24
177	Calcitriol treatment in vitamin D-dependent and vitamin D-resistant rickets. Metabolism: Clinical and Experimental, 1990, 39, 10-12.	1.5	25
178	Vitamin D metabolism in rats with adjuvant-induced arthritis. Journal of Bone and Mineral Research, 1990, 5, 905-913.	3.1	28
179	Perinatal Serum Bone Gla-Protein and Vitamin D Metabolites in Preterm and Fullterm Neonates*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 588-591.	1.8	45
180	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. Journal of Bone and Mineral Research, 1987, 2, 595-610.	3.1	4,558

#	Article	IF	Citations
181	InVitroMetabolism of 25-Hydroxycholecalciferol by Isolated Cells from Human Decidua*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 880-885.	1.8	120
182	Renal Osteodystrophy in Children Treated with 1,25â€Dihydroxyâ€Cholecalciferol [1,25â€(OH)₂D₃]: Histologic Bone Studies. Acta Paediatrica, International Journal of Paediatrics, 1984, 73, 315-324.	0.7	10
183	Ã‰tude dÃ©mographique et gÃ©nÃ©alogique de deux maladies hÃ©rÃ©ditaires au Saguenay. Cahiers QuÃ©bÃ©cois De DÃ©mographie, 1984, 13, 117-137.	0.5	11
184	Effects of phosphate and 1,25(OH)2D3 on in vitro bone collagen synthesis in the hypophosphatemic mouse. Calcified Tissue International, 1983, 35, 383-391.	1.5	10
185	Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcified Tissue International, 1983, 35, 443-448.	1.5	96
186	Panostotic fibrous dysplasia: A congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. American Journal of Medical Genetics Part A, 1983, 14, 725-735.	2.4	22
187	Normal Serum 25-Hydroxyvitamin D Levels in Phenobarbital-Treated Toddlers. Developmental Pharmacology and Therapeutics, 1983, 6, 157-161.	0.2	6
188	Histological Osteomalacia Due to Dietary Calcium Deficiency in Children. New England Journal of Medicine, 1982, 307, 584-588.	13.9	100
189	Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcified Tissue International, 1982, 34, 158-164.	1.5	42
190	Vitamin D metabolism in preterm infants: Serum calcitriol values during the first five days of life. Journal of Pediatrics, 1981, 99, 640-643.	0.9	64
191	Vitamin D dependency: Replacement therapy with calcitriol. Journal of Pediatrics, 1981, 99, 26-34.	0.9	116
192	Influence of vitamin D₃ states, phenobarbital, and diphenylhydantoin treatment on the plasma 25-hydroxyvitamin D₃ concentrations in the rat. Canadian Journal of Physiology and Pharmacology, 1981, 59, 1073-1081.	0.7	9
193	The collagen crosslinking in the hypophosphatemic male mouse. Calcified Tissue International, 1981, 33, 77-79.	1.5	5
194	Serum 1,25-dihydroxyvitamin D concentration in hypophosphatemic vitamin D-resistant rickets. Calcified Tissue International, 1981, 33, 173-175.	1.5	74
195	Hypoparathyroidism during Pregnancy: Treatment with Calcitriol. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 810-813.	1.8	65
196	Bone Response to Phosphate Salts, Ergocalciferol, and Calcitriol in Hypophosphatemic Vitamin D-Resistant Rickets. New England Journal of Medicine, 1980, 303, 1023-1031.	13.9	267
197	Kinetic alterations in rat liver microsomal cholecalciferol 25-hydroxylase associated with phenobarbital administration. Biochemical Pharmacology, 1980, 29, 441-445.	2.0	2
198	In vitro sulfate turnover in osteogenesis imperfecta congenita and tarda. American Journal of Medical Genetics Part A, 1979, 4, 349-355.	2.4	5

#	Article	IF	Citations
199	Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: Evidence for a defect in the brush border membrane. Kidney International, 1978, 14, 236-244.	2.6	163
200	Collagen changes in the human uterine cervix at parturition. American Journal of Obstetrics and Gynecology, 1978, 130, 748-753.	0.7	137
201	Hypophosphatemic nonrachitic bone disease: An entity distinct from X-linked hypophosphatemia in the renal defect, bone involvement, and inheritance. American Journal of Medical Genetics Part A, 1977, 1, 101-117.	2.4	70
202	Replacement therapy for inherited enzyme deficiency: Liver orthotopic transplantation in Niemann-Pick disease type A. American Journal of Medical Genetics Part A, 1977, 1, 229-239.	2.4	66
203	Intestinal Phosphate Transport in Familial Hypophosphatemic Rickets. Pediatric Research, 1976, 10, 691-696.	1.1	27
204	Response to Crystalline 1Î±-Hydroxyvitamin D3 in Vitamin D Dependency. Pediatric Research, 1975, 9, 593-599.	1.1	80
205	Use of Phosphate and Vitamin D to Prevent Dwarfism and Rickets in X-Linked Hypophosphatemia. New England Journal of Medicine, 1972, 287, 481-487.	13.9	195
206	Transport and metabolism of sarcosine in hypersarcosinemic and normal phenotypes. Journal of Clinical Investigation, 1971, 50, 2313-2322.	3.9	17